WASHINGTON, Feb 21 (Reuters) - U.S. regulators on Thursday cleared a new drug made by Wyeth WYE.N. to treat the blood-clotting disorder hemophilia.
The Food and Drug Administration said it licensed Wyeth's Xyntha anti-hemophilic factor, a genetically engineered form of a protein expressed in the blood, to control and prevent bleeding in patients with hemophilia type A. (Reporting by Kim Dixon; editing by Jeffrey Benkoe)
NEW YORK (Reuters) - Tighter security measures at U.S. airports following an attempt to blow up a Detroit-bound jet could dampen enthusiasm for air travel, hurting the airline industry just as it seemed poised to recover from a period of bruising losses, some industry experts say.
The attraction of bombing airliners means the aviation industry has to be constantly vigilant in its fight against attackers. Full Article
With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
